發(fā)布時間：2018-06-19 21:59

  本文選題：TIGAR + 凋亡　； 參考：《蘇州大學(xué)》2015年博士論文

【摘要】：目的:觀察化療藥表阿霉素對肝癌細(xì)胞p53誘導(dǎo)的糖酵解和凋亡調(diào)節(jié)子(TIGAR)蛋白表達(dá)的影響以及TIGAR在肝癌細(xì)胞對表阿霉素化療耐受中的作用;探討TIGAR影響肝癌細(xì)胞對表阿霉素耐藥的初步機(jī)制。方法:Western blot法檢測表阿霉素對肝癌細(xì)胞TIGAR蛋白表達(dá)的影響;采用小干擾RNA技術(shù)干擾肝癌細(xì)胞TIGAR表達(dá)后通過MTT及克隆形成實驗分別檢測干擾TIGAR表達(dá)聯(lián)合表阿霉素治療對肝癌細(xì)胞生存的短期和長期影響;Annexin V-FITC/PI雙染流式細(xì)胞術(shù)檢測干擾TIGAR表達(dá)聯(lián)合表阿霉素治療對肝癌細(xì)胞凋亡的影響;采用慢病毒構(gòu)建的TIGAR-sh RNA感染Hep G2肝癌細(xì)胞,經(jīng)嘌呤霉素篩選,western blot及細(xì)胞免疫熒光法檢測干擾效率,得到穩(wěn)轉(zhuǎn)株后通過裸鼠成瘤實驗檢測干擾TIGAR表達(dá)對肝癌腫瘤形成、生長及其對表阿霉素化療療效的影響;2’,7’-二氯二氫熒光素雙醋酸鹽(DCFH2-DA)標(biāo)記流式細(xì)胞術(shù)、GSH檢測試劑盒及NADPH檢測試劑盒分別檢測細(xì)胞內(nèi)活性氧(ROS)水平、GSH/GSSG比值及NADPH水平;Western blot檢測細(xì)胞內(nèi)凋亡相關(guān)蛋白水平;細(xì)胞免疫熒光法、western blot及電鏡技術(shù)檢測干擾TIGAR表達(dá)對肝癌細(xì)胞自噬的影響;彗星實驗檢測細(xì)胞DNA損傷情況;采用細(xì)胞核質(zhì)分離技術(shù)分離細(xì)胞核后western blot分別檢測胞漿及胞核中TIGAR的表達(dá);運用細(xì)胞免疫熒光及western blot技術(shù)檢測DNA損傷修復(fù)中相關(guān)蛋白ATM、Cdk5等的表達(dá)。結(jié)果:為了研究表阿霉素對肝癌細(xì)胞TIGAR表達(dá)的影響,我們采用不同濃度的表阿霉素作用肝癌Hep G2細(xì)胞不同時間后,western blot檢測TIGAR表達(dá),結(jié)果顯示,低濃度短時間的表阿霉素作用可誘導(dǎo)Hep G2肝癌細(xì)胞TIGAR表達(dá),高濃度長時間的表阿霉素作用后TIGAR表達(dá)下調(diào)。且表阿霉素誘導(dǎo)的TIGAR表達(dá)是依賴p53變化的。為了進(jìn)一步探討表阿霉素誘導(dǎo)的肝癌細(xì)胞TIGAR高表達(dá)在肝癌細(xì)胞對表阿霉素療效中的作用,我們采用小干擾RNA干擾肝癌Hep G2細(xì)胞TIGAR表達(dá)后通過MTT、克隆形成實驗及流式等體外實驗檢測發(fā)現(xiàn),干擾TIGAR表達(dá)聯(lián)合表阿霉素作用后肝癌Hep G2細(xì)胞的存活明顯下降,細(xì)胞凋亡顯著增加;此外,通過體內(nèi)實驗即裸鼠成瘤實驗檢測干擾TIGAR表達(dá)對肝癌細(xì)胞成瘤的影響以及移植瘤對表阿霉素療效的影響,結(jié)果顯示,干擾TIGAR表達(dá)抑制肝癌的形成和生長,同時也增加了其對表阿霉素的化療敏感性。研究還發(fā)現(xiàn),不僅對于肝癌細(xì)胞,表阿霉素也增加了肺癌A549細(xì)胞的TIGAR表達(dá)且干擾TIGAR表達(dá)增加肺癌A549細(xì)胞對表阿霉素的化療敏感性。腫瘤的化療耐受與多種機(jī)制相關(guān),其中ROS適應(yīng)性反應(yīng)、細(xì)胞自噬及細(xì)胞DNA損傷修復(fù)在腫瘤化療耐藥的形成中起著重要作用,TIGAR作為p53下游基因,通過抑制細(xì)胞糖酵解及增加磷酸戊糖通路產(chǎn)生NADPH降低細(xì)胞內(nèi)ROS水平,從而降低ROS引起的細(xì)胞凋亡、ROS介導(dǎo)的細(xì)胞自噬激活及ROS誘導(dǎo)的DNA損傷修復(fù),此外,磷酸戊糖通路的激活增加了DNA合成原料核苷酸的生成,有利于受損DNA的修復(fù)。因此,為了進(jìn)一步探討干擾TIGAR表達(dá)在肝癌細(xì)胞對表阿霉素化療增敏中的機(jī)制,我們從細(xì)胞凋亡、細(xì)胞自噬及細(xì)胞DNA損傷修復(fù)三方面來進(jìn)行研究。第一,干擾TIGAR表達(dá)顯著增加表阿霉素誘導(dǎo)的肝癌細(xì)胞凋亡,并與ROS水平增加、Caspase3激活相關(guān)。采用NADPH或NAC清除細(xì)胞ROS水平或采用Z-VAD-FMK抑制Caspase3后可部分減輕細(xì)胞凋亡。提示,干擾TIGAR表達(dá)增加肝癌細(xì)胞對表阿霉素化療敏感性與干擾TIGAR表達(dá)增加細(xì)胞凋亡有關(guān)。第二,干擾TIGAR表達(dá)顯著增加表阿霉素誘導(dǎo)的肝癌細(xì)胞自噬激活,表現(xiàn)為LC3I向LC3 II轉(zhuǎn)化增加、自噬體增多及自噬底物p62蛋白水平的下調(diào)。干擾TIGAR表達(dá)增加表阿霉素誘導(dǎo)的肝癌細(xì)胞自噬激活通過增加細(xì)胞ROS水平及抑制m TOR通路來實現(xiàn),NADPH清除ROS后可部分抑制干擾TIGAR表達(dá)聯(lián)合表阿霉素作用激活的自噬。采用3-MA或干擾Atg5抑制細(xì)胞自噬后進(jìn)一步增加了干擾TIGAR表達(dá)聯(lián)合表阿霉素作用所致的肝癌細(xì)胞凋亡。提示,干擾TIGAR表達(dá)增加表阿霉素誘導(dǎo)的肝癌細(xì)胞自噬激活對細(xì)胞的生存起保護(hù)作用,能夠抵抗表阿霉素的毒性作用,在此基礎(chǔ)上抑制細(xì)胞自噬能得到額外的抗腫瘤效果。即干擾TIGAR誘導(dǎo)的細(xì)胞自噬激活降低肝癌細(xì)胞對表阿霉素的化療敏感性。第三,TIGAR增加磷酸戊糖通路產(chǎn)生NADPH減少細(xì)胞ROS從而減少DNA損傷,此外,產(chǎn)生的戊糖作為DNA合成原料有利于受損DNA的修復(fù)。表阿霉素除了誘導(dǎo)肝癌細(xì)胞TIGAR表達(dá)外還促進(jìn)其入核,調(diào)控腫瘤細(xì)胞DNA損傷修復(fù)。干擾TIGAR表達(dá)顯著增加表阿霉素誘導(dǎo)的肝癌細(xì)胞DNA損傷,當(dāng)給予磷酸戊糖途徑產(chǎn)生的戊糖、NADPH或ROS清除劑NAC后可部分緩解DNA損傷。提示干擾TIGAR表達(dá)除了通過抑制磷酸戊糖通路增加表阿霉素誘導(dǎo)的肝癌細(xì)胞DNA損傷外,還有其他機(jī)制的存在。進(jìn)一步實驗研究顯示,TIGAR通過調(diào)節(jié)Cdk5來磷酸化DNA損傷修復(fù)關(guān)鍵蛋白ATM進(jìn)而調(diào)控細(xì)胞DNA損傷修復(fù)。綜上,TIGAR通過磷酸戊糖途徑及Cdk5-AMT信號通路來調(diào)控表阿霉素對肝癌細(xì)胞DNA的損傷與修復(fù)進(jìn)而影響肝癌細(xì)胞對表阿霉素的化療敏感性。結(jié)論:表阿霉素誘導(dǎo)肝癌細(xì)胞TIGAR表達(dá);干擾TIGAR表達(dá)增加肝癌細(xì)胞對表阿霉素的化療敏感性,其機(jī)制涉及細(xì)胞凋亡增加、自噬水平激活以及細(xì)胞DNA的損傷與修復(fù)。TIGAR表達(dá)在肝癌細(xì)胞對表阿霉素耐受中的作用提示TIGAR成為抗腫瘤治療作用靶點的可能,為臨床抗腫瘤治療尤其是對表阿霉素耐受的肝癌治療提供理論基礎(chǔ)及依據(jù)。
[Abstract]:Objective: To observe the effect of epirubicin on the expression of glycolysis and apoptosis regulator (TIGAR) induced by p53 in hepatoma cells and the role of TIGAR in the tolerance of liver cancer cells to adriamycin chemotherapy, and to explore the mechanism of TIGAR influence on the resistance of liver cancer cells to adriamycin. Methods: Western blot assay was used to detect epirubicin to liver cancer. The effect of the expression of TIGAR protein in cells; using small interference RNA technique to interfere with the expression of TIGAR in hepatoma cells, the short-term and long-term effects of TIGAR expression combined with epirubicin on the survival of hepatoma cells were detected by MTT and clonogenic experiments, and Annexin V-FITC/PI double dye flow cytometry interfered with TIGAR expression combined with epirubicin The effect of treatment on the apoptosis of hepatoma cells; TIGAR-sh RNA infected by lentivirus, Hep G2 hepatoma cells, the screening of purinomycin, Western blot and cell immunofluorescence method to detect the interference efficiency. After the stable transgenic mice were obtained, the interference of TIGAR expression to the formation of the cancer of the liver cancer, the growth and the chemotherapy of doxorubicin on the liver cancer were detected. Effect: 2 ', 7' - two chlorine two fluorescein diacetate (DCFH2-DA) labeled flow cytometry, GSH detection kit and NADPH detection kit to detect intracellular reactive oxygen species (ROS) level, GSH/GSSG ratio and NADPH level, Western blot detection of intracellular apoptotic phase protein level, cell immunofluorescence, Western blot and electron microscopy The effect of interfering TIGAR expression on autophagy of hepatoma cells was detected; Comet assay was used to detect DNA damage in cells; Western blot was used to detect the expression of TIGAR in cytoplasm and nucleus after cell nuclear separation technique, and cell immunofluorescence and Western blot were used to detect the associated protein ATM, Cdk5, etc. in DNA damage repair. Results: in order to study the effect of epirubicin on the expression of TIGAR in hepatoma cells, we used Western blot to detect TIGAR expression after different concentrations of epirubicin on the liver cancer Hep G2 cells. The results showed that the low concentration of epirubicin could induce the TIGAR expression of Hep G2 hepatoma cells, and the high concentration and long time table could be used. The expression of TIGAR was down regulated by doxorubicin, and the expression of epirubicin induced TIGAR was dependent on p53. In order to further explore the effect of TIGAR high expression of epirubicin induced hepatoma cells in the therapeutic effect of hepatoma cells on epuxorubicin, we used small interference RNA to interfere with the expression of TIGAR in Hep G2 cells to form solid clones through MTT. In vitro test and flow test, it was found that the survival of Hep G2 cells in HCC significantly decreased and apoptosis increased significantly after TIGAR expression combined with epirubicin. In addition, the effects of interfering TIGAR expression on the tumor formation of hepatoma cells and the effect of xenograft on adriamycin effect were detected by in vivo experiments. The results show that interfering TIGAR expression inhibits the formation and growth of liver cancer and also increases its sensitivity to epuxorubicin. The study also found that epirubicin also increased the TIGAR expression of lung cancer A549 cells and interfered with the expression of TIGAR in lung cancer cells and increased the chemosensitivity of A549 cells to epirubicin. Tolerance is related to a variety of mechanisms, in which ROS adaptive response, cell autophagy and cell DNA damage repair play an important role in the formation of chemotherapeutic drug resistance. TIGAR, as a downstream p53 gene, reduces cell apoptosis induced by ROS by inhibiting cell glycolysis and increasing NADPH in pentose phosphoric acid pathway to reduce the level of intracellular ROS induced by ROS, ROS Mediated cell autophagy activation and ROS induced DNA damage repair. In addition, the activation of pentose phosphate pathway increases the formation of DNA synthesis nucleotides and is beneficial to the repair of damaged DNA. Therefore, in order to further explore the mechanism of interference TIGAR expression in the chemosensitivity of hepatoma cells to adriamycin chemotherapy, we are from cell apoptosis and autophagy. Three aspects of cell DNA damage repair were studied. First, interfering TIGAR expression significantly increased the apoptosis of HCC induced by epirubicin, and was related to the increase of ROS level and Caspase3 activation. NADPH or NAC was used to remove the cell ROS level or to reduce the apoptosis after the use of Z-VAD-FMK to inhibit Caspase3. It suggested that the expression of TIGAR increased in TIGAR. The chemosensitivity of hepatoma cells to epuxorubicin was associated with increased cell apoptosis by interfering TIGAR expression. Second, interfering TIGAR expression significantly increased autophagy induced by epirubicin induced hepatoma cells, showing an increase in LC3I to LC3 II, the increase of autophagosome and the downregulation of p62 protein levels of autophagic substrates. Interference with TIGAR expression increased epirubicin induced induction. Autophagy of hepatoma cells is activated by increasing cell ROS level and inhibiting the m TOR pathway. NADPH scavenging ROS can partially inhibit the interference of TIGAR expression and autophagy activated by the action of epirubicin. 3-MA or interference Atg5 inhibits autophagy of the cells to further increase the interference of the TIGAR table to the action of the combined adriamycin action. It is suggested that the interference of TIGAR expression to increase the autophagy induced by epirubicin induced activation of autophagy can protect the survival of the cells, and can resist the toxicity of epirubicin. On this basis, the inhibition of autophagy by cell autophagy can result in an additional anti-tumor effect. That is, interfering with autophagy induced by TIGAR to reduce hepatoma cells to opiophos Third, TIGAR increase the pentose phosphate pathway to produce NADPH to reduce cell ROS and reduce DNA damage. In addition, the pentose produced as a DNA synthetic material is beneficial to the repair of damaged DNA. Epirubicin also promotes its nucleation in addition to inducing the TIGAR expression of hepatoma cells and regulates the repair of DNA damage in tumor cells. Significantly increased DNA damage induced by epirubicin, when pentose pentose produced by pentose phosphate pathway was given, NADPH or ROS scavenger NAC could partially alleviate DNA damage. It suggests that there are other mechanisms in the presence of interference TIGAR expression in addition to increasing the DNA damage induced by epirubicin pathway by inhibiting the pentose phosphate pathway. The experimental studies have shown that TIGAR regulates the DNA damage and repair key protein ATM by regulating the phosphorylation of Cdk5 to regulate the repair of cell DNA damage. To sum up, TIGAR regulates the damage and repair of epirubicin on the liver cancer cell DNA by pentose phosphate pathway and Cdk5-AMT signaling pathway and then affects the chemosensitivity of hepatoma cells to adriamycin. Epirubicin induced the expression of TIGAR in hepatoma cells; interference with TIGAR expression increases the chemosensitivity of hepatoma cells to adriamycin, and its mechanism involves increased apoptosis, activation of autophagy, DNA damage and the role of.TIGAR expression in the tolerance of liver cancer cells to adriamycin tolerance, suggesting that TIGAR becomes an antitumor therapeutic target. It may provide a theoretical basis and basis for clinical antitumor therapy, especially for the treatment of epirubicin tolerant liver cancer.
【學(xué)位授予單位】：蘇州大學(xué)
【學(xué)位級別】：博士
【學(xué)位授予年份】：2015
【分類號】：R735.7

【共引文獻(xiàn)】

相關(guān)期刊論文 前10條

1 Naima Hammoudi;Kausar Begam Riaz Ahmed;Celia Garcia-Prieto;;Metabolic alterations in cancer cells and therapeutic implications[J];癌癥;2011年08期

2 朱偉良;李虹義;張健;汪森明;張積仁;;肝動脈栓塞化療聯(lián)合氬氦刀消融和無水乙醇注射治療肝癌[J];南方醫(yī)科大學(xué)學(xué)報;2009年08期

3 麥筱莉;李保新;范海健;張秀明;戴峰;臧鳳超;;原位裸小鼠肝癌模型的建立及高場MR成像的實驗研究[J];放射學(xué)實踐;2011年12期

4 季偉;郭英君;楊妍;張玉喜;;肝動脈插管介入化療治療原發(fā)性肝癌患者肝功能的變化[J];實用肝臟病雜志;2010年04期

5 季偉;郭英君;楊妍;張玉喜;;血清HBV DNA與肝動脈化療栓塞術(shù)后肝癌復(fù)發(fā)的相關(guān)性研究[J];實用肝臟病雜志;2010年06期

6 竇莉伶;付春云;;“炎癥與腫瘤”的研究進(jìn)展及對腫瘤防治的啟示[J];國際檢驗醫(yī)學(xué)雜志;2012年10期

7 劉鵬啟;丁樹哲;邵月;;P53對線粒體的能量調(diào)控與運動適應(yīng)的可能機(jī)制[J];廣州體育學(xué)院學(xué)報;2008年03期

8 張建軍;侯培珍;;血清甲胎蛋白和血管內(nèi)皮生長因子對肝癌患者肝動脈栓塞的評估[J];包頭醫(yī)學(xué)院學(xué)報;2012年06期

9 孫斌;陳磊;劉振宇;錢海華;施樂華;殷正豐;;腫瘤相關(guān)肝星狀細(xì)胞促進(jìn)肝癌細(xì)胞上皮間質(zhì)轉(zhuǎn)化和遷移[J];第二軍醫(yī)大學(xué)學(xué)報;2013年05期

10 康振;肖恩華;;肝細(xì)胞肝癌TACE術(shù)后血管改變研究進(jìn)展[J];國際醫(yī)學(xué)放射學(xué)雜志;2013年04期

相關(guān)會議論文 前9條

1 Zhi-Mei Huang;Wang Li;Sheng Li;Fei Gao;Qi-Ming Zhou;Fang-Ming Wu;Ni He;Chang-Chuan Pan;Jian-Chuan Xia;Pei-Hong Wu;Ming Zhao;;Cytokine-induced Killer Cells in Combination With Transcatheter Arterial Chemoembolization and Radiofrequency Ablation for Hepatocellular Carcinoma Patients[A];第九屆中國腫瘤微創(chuàng)治療學(xué)術(shù)大會論文集[C];2013年

2 李春竹;戚新明;任進(jìn);;miR-491-3p在MDR1介導(dǎo)的人肝癌多藥耐藥中的作用[A];2013年中國藥學(xué)大會暨第十三屆中國藥師周論文集[C];2013年

3 Xuejun Jiang;Zunzhen Zhang;;Sodium arsenite and arsenic trioxide differently affect the oxidative stress,genotoxicity and apoptosis in A549 cells:an implication for the paradoxical mechanism[A];第十一屆全國博士生學(xué)術(shù)年會（生物醫(yī)藥專題）論文集（下冊，墻報P25-P48）[C];2013年

4 Jian Xiao;Wanglei Qu;Qiong Chen;;A Novel Monocarbonyl Analogue of Curcumin Induced Human Ovarian Cancer Cells Apoptosis Via Activation Endoplasmic Reticulum Stress and Autophagy Signaling Pathway[A];抗腫瘤藥物研究新進(jìn)展與腫瘤個性化藥物治療論壇論文集[C];2013年

5 羅君;邵國良;鄭家平;陳玉堂;姚征;曾暉;郝偉遠(yuǎn);;原發(fā)性肝癌肝動脈化療栓塞術(shù)后腹痛的發(fā)生規(guī)律及影響因素[A];浙江省抗癌協(xié)會腫瘤介入診療專業(yè)委員會2013年學(xué)術(shù)年會論文集[C];2013年

6 劉敏霞;周可成;曹毅;;新的肺癌相關(guān)基因MCRS1病理生理功能研究[A];第十六屆中國科協(xié)年會——分3環(huán)境污染及職業(yè)暴露與人類癌癥學(xué)術(shù)研討會論文集[C];2014年

7 王彩蓮;;肺癌抗血管生成的治療機(jī)制及最新進(jìn)展[A];中國腫瘤內(nèi)科進(jìn)展 中國腫瘤醫(yī)師教育（2014）[C];2014年

8 ;Radiofrequency Ablation following Transarterial Chemoembolization for Patients with BCLC B,C stage Hepatocellular Carcinoma[A];第四屆全國醫(yī)學(xué)影像中西醫(yī)結(jié)合青年醫(yī)師論壇暨第四屆《中國中西醫(yī)結(jié)合影像學(xué)雜志》編委會會議資料匯編[C];2015年

9 劉瑞;何姝霖;鄭紅剛;李衛(wèi)東;花寶金;齊鑫;裴迎霞;張蕓;;肺瘤平膏及其聯(lián)合塞來昔布干預(yù)時間對Lewis肺癌小鼠不同腫瘤微環(huán)境中COX-2表達(dá)的影響[A];第一屆青年中西醫(yī)結(jié)合腫瘤學(xué)術(shù)論壇論文集[C];2015年

相關(guān)博士學(xué)位論文 前10條

1 樊慶勝;VEGF、VEGFR-2及PDGF-BB聯(lián)檢在TACE聯(lián)合索拉非尼治療肝細(xì)胞肝癌中的價值[D];中國人民解放軍軍醫(yī)進(jìn)修學(xué)院;2011年

2 熊微;溫度/pH雙重敏感納米凝膠的構(gòu)建、藥物偶聯(lián)與新型血管栓塞材料的研究[D];華中科技大學(xué);2011年

3 沈彥偉;腫瘤微環(huán)境中CD4~+T細(xì)胞調(diào)控及Treg細(xì)胞亞型與腫瘤相關(guān)性研究[D];浙江大學(xué);2011年

4 張幸鼎;DRAM1通過溶酶體調(diào)節(jié)自噬和細(xì)胞凋亡[D];蘇州大學(xué);2011年

5 楊林;原發(fā)性肝癌MDCT灌注成像的動物實驗與臨床研究[D];四川大學(xué);2007年

6 劉展;腦膠質(zhì)瘤細(xì)胞中線粒體DNA突變及Idebenone對U251和C6細(xì)胞活性抑制的研究[D];四川大學(xué);2007年

7 劉凌曉;基因干擾肝腸鈣黏附蛋白聯(lián)合p53分子靶向治療肝癌的實驗研究[D];復(fù)旦大學(xué);2008年

8 孟憲宇;周圍神經(jīng)感覺束和運動束的比較蛋白質(zhì)組學(xué)研究[D];吉林大學(xué);2010年

9 宋傳旺;腫瘤微環(huán)境對肥大細(xì)胞在腫瘤生長中作用的影響[D];華中科技大學(xué);2010年

10 粟娟;CD147在惡性黑素色瘤細(xì)胞糖酵解過程中的作用及機(jī)制研究[D];中南大學(xué);2010年

相關(guān)碩士學(xué)位論文 前10條

1 劉養(yǎng)歲;雷公藤甲素對肝癌細(xì)胞化療敏感性的影響[D];南京醫(yī)科大學(xué);2010年

2 盛名;肝細(xì)胞癌經(jīng)動脈栓塞與經(jīng)動脈化療栓塞療效比較的Meta分析[D];廣西醫(yī)科大學(xué);2011年

3 俞璐;耐力運動對不同月齡ICR小鼠P53/SCO1/SCO2基因表達(dá)的影響[D];華東師范大學(xué);2011年

4 胡揚喜;肝動脈栓塞化療治療肝癌療效及對肝功能的影響的研究[D];廣州醫(yī)學(xué)院;2010年

5 朱蔚;恩度聯(lián)合欖香烯治療晚期肝癌的臨床觀察[D];第四軍醫(yī)大學(xué);2011年

6 同李平;食管癌組織中神經(jīng)纖維分布的形態(tài)學(xué)研究及SP/NK1-R信號對Eca9706細(xì)胞的促生長作用[D];第四軍醫(yī)大學(xué);2011年

7 周利華;采用不同介入治療方案治療大鼠肝癌的實驗研究[D];華中科技大學(xué);2011年

8 杜昂鷹;TRAIL對卵巢癌細(xì)胞株SKOV-3，A2780，，PA-1的作用[D];四川大學(xué);2006年

9 孫麗麗;凋亡素基因?qū)θ撕戆┘?xì)胞的抑制效應(yīng)研究[D];吉林大學(xué);2007年

10 胡波;轉(zhuǎn)STGC3基因CNE2細(xì)胞系在雌雄性裸鼠成瘤的差異分析[D];南華大學(xué);2007年

本文編號：2041463